Press release distribution for biotech: the trial-results rule

You may announce trial results; you may not present the drug as safe or effective for the purpose under investigation. Report the endpoint, the arm sizes and the statistics, and let the reader draw the inference. No newswire in this survey publishes a review step for pre-approval promotion, so the compliance work sits entirely with you, on a release the wire will publish either way.

A biotech press release is written against a sentence in the Code of Federal Regulations that applies to almost no other sector. 21 CFR 312.7(a) reads: "A sponsor or investigator, or any person acting on behalf of a sponsor or investigator, shall not represent in a promotional context that an investigational new drug is safe or effective for the purposes for which it is under investigation or otherwise promote the drug."

"Any person acting on behalf of a sponsor" includes your agency, and it includes the distributor that transmits the release. It does not include the wire's editorial desk, which will not check it. No newswire in this survey publishes a review step for pre-approval promotion, and the one time a wire's rules come close — Newsfile's ban on unregulated treatments, EIN Presswire's ban on all supplements — it is aimed at consumer health products, not at clinical-stage sponsors.

So the compliance work sits entirely with you, on a release that a wire will happily publish either way. That asymmetry is the single most important thing to understand about buying distribution in this sector.

What the rule does to the copy

The regulation is aimed at promotion, not at communication. Reporting results, disclosing data and engaging in scientific exchange are not what it prohibits; representing an unapproved product as safe or effective is. The line runs through the adjectives.

• "Demonstrated a statistically significant reduction in the primary endpoint" describes a result.
• "Effective in treating" characterises an unapproved product.
• "Well tolerated" is a safety representation about an investigational drug and is one of the most common phrases to survive into a release unexamined.
• "Breakthrough," "game-changing," "promising new treatment" are promotional framing attached to a product that has no approved indication.

The practical drafting discipline is to state what the trial measured, in what population, against what comparator, with the endpoint named and the confidence interval given, and to let the numbers make whatever case they make. That is also better copy: a specific endpoint result is quotable by a trade reporter, and an adjective is not. We set out what a release needs structurally separately.

This is not legal or regulatory advice, and it is deliberately not a checklist. The FDA's promotional rules interact with your IND, your indication and your jurisdiction, and the version of this that matters is the one your regulatory affairs function signs.

If you are listed, the release is also a disclosure

For a public biotech, trial data is material non-public information and the release is the mechanism that makes it public. Regulation FD, 17 CFR 243.100, requires public disclosure simultaneously with an intentional selective disclosure and promptly after an unintentional one. In practice that couples the release to the market calendar and to your investor-relations counsel rather than to a marketing schedule, and it makes the wire's timestamp part of the compliance record.

It also changes what you are buying. A biotech data release is usually bought on a financial circuit rather than a general one, because the audience that must receive it simultaneously is an investor audience. PR Newswire's 2024 domestic card prices World Financial Markets at $5,760 per 400 words and Premier Global at $10,375, against $1,020 for US1 National. Newsfile, owned by TMX, reaches Refinitiv, FactSet, Factiva and Bloomberg terminals and acts as an EDGAR and SEDAR filing agent — and publishes no price whatsoever. Those are the products that exist for this job, and the gap between them and a $199 self-serve release is not a discount, it is a different service.

The word count is not a detail here

A data release carries a study design paragraph, an endpoint table, an about-the-trial section, an about-the-company boilerplate and a forward-looking statements block. That is comfortably 900 to 1,200 words before anyone edits.

On the tier-one meter, 400 words are included and each additional 100 costs $325 on US1 National and $1,535 on World Financial Markets. A 1,000-word release on the financial circuit is $5,760 plus six overage blocks — the overage alone exceeds the entire cost of most self-serve packages. ACCESS Newswire and Newswire.com publish unlimited words on their paid tiers at $865 to $1,205 and $399 to $965. Whether that substitution is acceptable depends on whether you need terminal reach; if you do, it is not. We took the whole rate card apart line by line if you want to price a specific draft.

The adjacent categories the wires do ban

Biotech proper is not a restricted category. The neighbouring ones are, and the boundary catches companies that do not think of themselves as being on the wrong side of it.

• EIN Presswire bans all supplements "irrespective of legality", and accepts pharmacies only conditionally, on prescription status and a US or UK site.
• Newsfile bans unregulated supplements and treatments.
• PRWeb refuses non-compliant pharmaceuticals, unsafe weight-loss products, misleading health supplements and sexual-enhancement products, and accepts prescription pharmaceuticals conditionally.
• PRUnderground bans supplements "regardless of legality or FDA status".

A nutraceutical spin-out, a medical-food company or a diagnostics business with a wellness SKU can find itself refused on a product line rather than on its science. The full published picture, by category, is worth reading before you budget.

What we sell, and where we are the wrong vendor

We are a reseller. Our packages run $599 to $899 and are fulfilled through wire partners. For a clinical-stage company announcing topline data, we are the wrong shape of vendor: you need terminal reach, a filing agent, and a desk that will hold an embargo, and none of those is a self-serve product. Say so to any storefront that tells you otherwise.

Where a syndication buy does make sense in this sector is the non-material announcement — a facility, a hire, a partnership without financial terms, a conference presentation notice. For those, what we add is that we open the published URLs afterwards and report what actually went live rather than what a supplier's pickup report claims — a sample report shows both labels in one table. We do not promise rankings, permanent pages, or that any named outlet will publish.

What we could not establish

Business Wire and ACCESS Newswire publish no content policy at all, and Business Wire publishes no rate card. For a sector where the wire's willingness to carry pre-approval data is a real question, that means two of the largest networks will not tell you their answer until a salesperson does. Get it in writing before the embargo is set.